| Literature DB >> 22354483 |
Ethan H Tittler1, Pho Nguyen, Kelly S Rue, Daniel V Vasconcelos-Santos, Jonathan C Song, John A Irvine, Ronald E Smith, Narsing A Rao, Samuel C Yiu.
Abstract
PURPOSE: The purpose of this study was to report outcomes of infectious scleritis after pterygium surgery, managed with antibiotic therapies and early scleral debridement.Entities:
Year: 2012 PMID: 22354483 PMCID: PMC3345049 DOI: 10.1007/s12348-012-0062-1
Source DB: PubMed Journal: J Ophthalmic Inflamm Infect ISSN: 1869-5760
Clinical features of a series of patients with infectious scleritis after pterygium surgery
| Patient | Age at presentation, sex | Pterygium adjunctive therapy | Previous therapy | Latency perioda (years) | Other presenting findings | Relevant medical history | Bacterioscopy/culture result | Histopathology of scleral tissue | Time between presentation and debridement (days) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 73, F | β-Irradiation | Tobramycin/dexamethasone gtts, ciprofloxacin ointment, glue | 8 | Serous RD/choroidal effusion, flare | Rheumatoid arthritis |
| Acute/chronic necrotizing scleritisc | 15, 23 |
| 2 | 61, F | N/A | – | N/A | – | – |
| Acute/chronic necrotizing scleritisc | 0 |
| 3 | 79, M | N/A | – | 20 | – | DM | No growth | Acute/chronic necrotizing scleritisc | 1 |
| 4 | 72, M | N/A | Erythromycin ointment | 1 | Choroidal effusion, posterior synechiae | Alcoholism | No growth | Acute/chronic necrotizing inflammation, fibrotic material within blood vessels, calcified materialc | 3 |
| 5 | 83, F | Mitomycin C | Ofloxacin gtts, moxifloxacin gtts | 0.33 | NVI | – |
| Acute/chronic necrotizing scleritis | 5 |
| 6 | 64, M | N/A | Diclofenac gtts, rimexolone gtts, prednisolone gtts, homatropine gtts | 3 | Choroidal effusion | DM |
| Acute necrotizing scleritisc | 2 |
| 7 | 92, F | N/A | Moxifloxacin gtts, gatifloxacin gtts, doxycyclin PO, moxifloxacin PO | N/A | Meibomian gland dysfunction | DM | No growth | Acute necrotizing inflammation | 16 |
| 8 | 64, F | Mitomycin C | Moxifloxacin gtts, erythromycin gtts | 1.5 | Serous RD, angle-closure | DM |
| Acute/chronic necrotizing scleritis | 14 |
| 9 | 49, M | N/A | Ofloxacin gtts | 3 | Glaucoma | DM |
| Chronic inflammation | 0, 28 |
| 10 | 68, F | N/A | – | N/A | Perforation | Rheumatoid arthritis |
| Necrotizing scleritisc | 18 |
| 11 | 65, F | N/A | Tobramycin/dexamethasone gtts, homatropine gtts | 12 | Choroidal detachments | – |
| Acute/chronic necrotizing scleritisc | 2 |
| 12 | 56, M | N/A | Removal of calcium plaque over pterygium resection site, fluorometholone gtts, prednisolone, neomycin/polymyxin B/dexamethasone ointment | 4 | Dry eye | – |
| – | 32 |
| 13 | 77, M | – | Prednisolone gtts, neomycin/polymyxin B/dexamethasone ointment, cyclopentolate, atropine, brimonidine | 3 | RD | – |
| – | 1 |
| Averages | 69.5 | 5.9b | 6.4 |
gtts drops, RD retinal detachment, N/A not available, DM diabetes mellitus, NVI iris neovascularization
aTime elapsed between pterygium excision and diagnosis of infectious scleritis
bNot including N/A data
cNegative special stains for bacteria (Gram) and fungi (Gomori methenamine silver)
Treatment outcomes after debridement and antibiotic therapy for infectious scleritis
| Patient | Hospital stay (days) | Complications | Antibiotic therapy | BCVA before debridement | BCVA after debridement | Follow-up (months) |
|---|---|---|---|---|---|---|
| 1 | 21 | Bleeding, scleral thinning, glaucoma, recurrence | Ciprofloxacin IV, gentamicin IV, tobramycin/dexamethasone gtts, ciprofloxacin ointment, fortified topical cefazolin and tobramycin and vancomycin and piperacillin gtts, ciprofloxacin ointment, ciprofloxacin PO | HM | 20/50 −2 | 86 |
| 2 | 2 | Severe scleral thinning, involvement of sclera at medial rectus | Levofloxacin IV, tobramycin/dexamethasone gtts, moxifloxacin gtts, gatifloxacin gtts | 20/100 | 20/40 | 30 |
| 3 | 1 | Scleral thinning, involvement of sclera at medial rectus | Fortified topical vancomycin and tobramycin gtts, gatifloxacin gtts, ciprofloxacin PO | 20/200 | 20/50 | 4 |
| 4 | 1 | Scleral thinning | Levofloxacin IV, fortified topical vancomycin and tobramycin gtts, gatifloxacin gtts, ciprofloxacin ointment | 20/100 −1 | 20/40 +2 | 14 |
| 5 | 3 | Scleral thinning, entropion, posterior synechiae | Cefazolin IV, fortified topical vancomycin and tobramycin gtts, ciprofloxacin gtts, moxifloxacin gtts | LP | CF | 4 |
| 6 | 2 | Severe scleral thinning requiring scleral patch graft and patch graft revision, involvement of sclera at medial rectus | Fortified topical vancomycin and tobramycin gtts, gatifloxacin gtts, gentamicin ointment, levofloxacin PO | 20/100 | 20/50 +1 | 5 |
| 7 | 1 | Scleral thinning, corneal necrosis with iris adhesion, prolapsed vitreous, elevated IOP | Levofloxacin IV, Fortified topical vancomycin and tobramycin gtts, gatifloxacin gtts, moxifloxacin gtts, moxifloxacin PO, fluconazole PO, doxycyclin PO | LP | LP | 4 |
| 8 | 7 | Severe scleral thinning, glaucoma | Gentamicin IV, ciprofloxacin IV, fortified topical tobramycin and vancomycin gtts, moxifloxacin gtts, loteprednol/tobramycin gtts, ciprofloxacin ointment, ciprofloxacin PO | 3/200 | 20/30 −2 | 26 |
| 9 | 5, 1 | Scleral thinning, recurrence | Fortified topical vancomycin and tobramycin gtts, moxifloxacin gtts, gatifloxacin gtts, ofloxacin gtts, ciprofloxacin gtts | 20/200 | HM | 44 |
| 10 | 0 | Scleral thinning, perforation, corneal haze, corneal epithelial defect that resolved | Fortified topical tobramycin and cefazolin gtts, ofloxacin gtts | 20/50 | 20/25 +1 | 62 |
| 11 | 14 | Scleral thinning, choroidal detachment, involvement of sclera under medial rectus | Ciprofloxacin IV, fortified topical tobramycin and piperacillin gtts, tobramycin/dexamethasone gtts, levofloxacin gtts, ofloxacin gtts | 20/80 +2 | 20/60 +1 | 6 |
| 12 | 4 | Scleral thinning, hypertrophic conjunctival growth, choroidal detachments, serous retinal detachment | Ciprofloxacin IV, fortified topical tobramycin gtts, levofloxacin gtts | 20/25 | 20/20 | 13 |
| 13 | 10 | Scleral thinning, phthisis | Fortified topical tobramycin and vancomycin gtts, levofloxacin gtts, ciprofloxacin ointment, ciprofloxacin PO, erythromycin gtts | CF @ 5′ | NLP | 102 |
gtts eye drops, IOP intraocular pressure, BCVA best-corrected visual acuity, LP light perception, CF counting finger, HM hand motion, NLP no light perception
Fig. 1Severe thinning of the sclera following debridement of infectious scleritis
A comparison of treatment outcomes of infectious scleritis reported in other studies
| Study | Number of patients | At least one debridement | Repeat debridement | Postoperative BCVA (%) | Mean hospital stay (days) | Postoperative complications (%) | Enucleations or eviscerations |
|---|---|---|---|---|---|---|---|
| Reynolds and Alfonso [ | 28 | 39% | N/A | N/A | N/A | N/A | 32% |
| Lin et al. [ | 30 | 87% | 62% | N/A | 32.5 | N/A | 3.3% |
| Hsiao et al. [ | 18 | 33% | N/A | NLP (22) | N/A | Recurrence (22) | 22% |
| LP (5.5) | Complicated cataract (28) | ||||||
| HM (5.5) | Serous retinal detachment (22) | ||||||
| CF (5.5) | |||||||
| 20/400 (5.5) | Choroidal detachment (17) | ||||||
| 20/200 (28) | |||||||
| 20/100 (11) | Choroidal and retinal detachment simultaneously (11) | ||||||
| 20/50 (11) | |||||||
| 20/30 (5.5) | |||||||
| Huang et al. [ | 3 | 100% | 0% | 20/200 (67) | N/A | Posterior synechiae (67) | 0% |
| 20/120 (33) | Cataract (67) | ||||||
| Cystoid macular edema (67) | |||||||
| Huang et al. [ | 16 | 44% | 13% | NLP (19) | N/A | Vitreous opacity (50) | 19% |
| LP (19) | Glaucoma (25) | ||||||
| HM (6) | Serous retinal or choroidal detachments (25) | ||||||
| 0.02 (6) | |||||||
| 0.1 (13) | |||||||
| 0.2 (6) | Cataract (13) | ||||||
| 0.3 (6) | Recurrence (13) | ||||||
| 0.5 (6) | |||||||
| 0.6 (6) | |||||||
| N/A (13) |
BCVA best-corrected visual acuity, N/A not available, NLP no light perception, LP light perception, HM hand motion